Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Jakafi
Pharma
CMS, Incyte settle lawsuit on classification of Opzelura
Incyte has dropped a lawsuit against the CMS, as the agency has agreed not to classify Opzelura together with Jakafi.
Kevin Dunleavy
Jun 23, 2026 1:32pm
Incyte reports Opzelura sales up 33% in 2025, plots '26 growth
Feb 10, 2026 11:48am
New Incyte CEO takes 'fresh look' at business, outlines BD plan
Aug 4, 2025 11:16am
Incyte, Novartis reach settlement in Jakafi royalty dispute
May 6, 2025 10:15am
Sun Pharma beats Incyte in appeals, teeing up US alopecia launch
Apr 10, 2025 10:00am
Incyte provides first guidance for JAK cream Opzelura
Feb 10, 2025 2:25pm
